Corporate News

Inmunotek Colombia celebrates its 10th anniversary

September 2023

INMUNOTEK COLOMBIA celebrated its tenth anniversary with a commemorative event at the Joint Congress of the Colombian Allergy and Immunology Associations held in the city of Barranquilla. Since its establishment as a subsidiary in 2013, INMUNOTEK COLOMBIA has continuously collaborated with Colombian clinicians and researchers in the field of allergic pathologies.
More info

Launching of ORALTEK in China

September 2023

INMUNOTEK has commenced operations in China with the launch of ORALTEK, a sublingual spray for allergen-specific immunotherapy. This follows the collaboration agreement with HOB-Biotech as partner for distribution and commercialization in China.
More info

Results with mannan-conjugated allergoids in EAACI

Conjugados alergoidesJune 2023

The clinical results obtained with the new mannan-conjugated allergoids for immunotherapy against birch pollen allergy have been presented in Hamburg (Germany) during the annual EAACI congress. These studies include the first phase 3 results showing their safety and efficacy.
More info

EAACI Hybrid Congress 2023

June 2023

INMUNOTEK has participated in the commercial exhibition of the annual EAACI congress that has taken place in Hamburg (Germany). Although the hybrid character of the congress has been maintained, an important number of participants have followed it in person and have approached INMUNOTEK's stand to obtain information about its products.
More info

Results with MV140 in North American Patients

May 2023

The results obtained with MV140 in North American patients with recurrent uncomplicated urinary tract infections were presented at the annual meeting of the American Urological Association in Chicago. The study conducted in North America (Canada) under real-world conditions indicates that MV140 has a high degree of efficacy and safety in the prevention of this type of infection.
More info